Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 439.7 DKK -3.7%
Market Cap: 2T DKK

EV/EBITDA
Enterprise Value to EBITDA

12.9
Current
23.3
Median
12.4
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
12.9
=
Enterprise Value
2T DKK
/
EBITDA
158B DKK
EBITDA Growth EV/EBITDA to Growth
DK
Novo Nordisk A/S
CSE:NOVO B
Average EV/EBITDA: 394.3
12.9
14%
0.9
US
Eli Lilly and Co
NYSE:LLY
33.3
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.5
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
10.1
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.6
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.3
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
11.4
2-Years Forward
EV/EBITDA
9.6
3-Years Forward
EV/EBITDA
8.6